Chimeric Therapeutics (CHM) has been granted a Japanese patent for its CLTX CAR technology.
The clinical-stage cell therapy company was issued the patent, entitled ‘Chimeric antigen receptors containing a chlorotoxin domain,’ which covers certain applications of the chimeric antigen receptor (CAR) technology using chlorotoxin (CLTX), including Chimeric’s CHM 1191 asset.
CHM 1101 (CLTX CAR T) is a therapy developed to treat patients with solid tumours. The drug is currently being studied in a phase one clinical trial in recurrent and progressive glioblastoma.
With the patent in hand, Chimeric holds a worldwide license to develop and commercialise this patent and related patent applications filed in other global territories.
“We are delighted to have patent protection granted for CLTX CAR therapies in Japan, the third largest pharmaceutical market in the world,” CEO and Managing Director Jennifer Chow said.
“The granting of this key Japan patent continues to expand the robust intellectual property portfolio underpinning our CLTX CAR pipeline assets.”
The company said it will continue to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets.
Chimeric Therapeutics was trading steady at 12.5 cents at 10:51 am AEST.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.